George Liu
Head of Early Development
Oncology
Harbour BioMed
China
Biography
Dr. George Liu is the Head of Early Development at Harbour BioMed (HBM). Before joining HBM, he was Director of Clinical Pharmacology for Novartis Oncology, where he was responsible for all aspects of clinical pharmacology for oncology product development in China. Prior to joining Novartis, Dr. Liu worked at Sanofi, GSK, and Guilford Pharmaceuticals where he held positions with increasing responsibilities for both nonclinical and clinical pharmacokinetics and contributed to the discovery and/or development, including regulatory approval, of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.
Research Interest
Oncology
